Zentalis shakes up PhIII plans in ovarian cancer; Halozyme's deal with Acumen; Korro's $117M private placement

2023-11-06

临床2期临床1期临床3期

Zentalis Pharma shakes up plans for Phase III in ovarian cancer: Zentalis announced Monday that it is no longer planning to test its lead candidate, azenosertib, in combination with chemotherapy in second-line platinum-sensitive ovarian cancer (PSOC) patients. The Phase III study was expected to start in the first quarter of next year. Instead, the company plans to test the wee1 inhibitor wee1 inhibitor as a first-line maintenance treatment for PSOC, pushing back the timeline for beginning a Phase III trial into 2025. Zentalis also shared updated results from a Phase I study in platinum-resistant ovarian cancer. The biotech is currently running a Phase II trial for which it plans to share topline data in 2025. Zentalis {ZNTL} shares fell over 20% after markets opened Monday. — Lei Lei Wu

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构